APA (7th ed.) Citation

S, K., S, J., KC, W., L, R., X, L., MA, D., . . . BGM, D. (2026). Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma. Blood cancer journal, 16(1), . https://doi.org/10.1038/s41408-026-01466-2

Chicago Style (17th ed.) Citation

S, Kumar, et al. "Linvoseltamab Versus Real-world International Myeloma Working Group Standard-of-care in Triple-class Exposed Relapsed/refractory Multiple Myeloma." Blood Cancer Journal 16, no. 1 (2026). https://doi.org/10.1038/s41408-026-01466-2.

MLA (9th ed.) Citation

S, Kumar, et al. "Linvoseltamab Versus Real-world International Myeloma Working Group Standard-of-care in Triple-class Exposed Relapsed/refractory Multiple Myeloma." Blood Cancer Journal, vol. 16, no. 1, 2026, https://doi.org/10.1038/s41408-026-01466-2.